KEY FEATURES
| Full Name | Cyclin Dependent Kinase 1 |
|---|---|
| Synonym | CDC2; CDC28A; CDK1; CDC28-A; CDKN1; P34CDC2; p34 protein kinase; Cell Division Control Protein 2 Homolog; Cell Division Cycle 2,G1 To S And G2 To M |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.15-10ng/mL |
| Sensitivity | 0.07ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human CDK1 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human CDK1. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human CDK1 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human CDK1, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human CDK1. You can calculate the concentration of Human CDK1 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human CDK1 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 0.51 | 0.92 | 4.25 | 0.51 | 0.9 | 3.83 |
| Standard deviation | 0.03 | 0.04 | 0.21 | 0.03 | 0.05 | 0.16 |
| CV(%) | 6.63 | 4.37 | 4.83 | 5.43 | 5.47 | 4.19 |
RECOVERY
The recovery of Human CDK1 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 84-100 | 91 |
| EDTA plasma (n=8) | 85-100 | 92 |
| Cell culture media (n=8) | 86-100 | 93 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human CDK1 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with CDK1 ELISA Kits
| CCNB1 ELISA Kit | publications with CDK1 and CCNB1 |
| CDC25C ELISA Kit | publications with CDK1 and CDC25C |
| CCNA2 ELISA Kit | publications with CDK1 and CCNA2 |
| CCNB2 ELISA Kit | publications with CDK1 and CCNB2 |
| CDC6 ELISA Kit | publications with CDK1 and CDC6 |
| BIRC5 ELISA Kit | publications with CDK1 and BIRC5 |
| BUB1 ELISA Kit | publications with CDK1 and BUB1 |
| BUB1B ELISA Kit | publications with CDK1 and BUB1B |
| CCNA1 ELISA Kit | publications with CDK1 and CCNA1 |
| RRM2 ELISA Kit | publications with CDK1 and RRM2 |
Pathways associated with CDK1 ELISA Kit
| APC/C-mediated Degradation Of Cell Cycle Proteins Pathway | APC/C-mediated Degradation Of Cell Cycle Proteins Pathway |
| APC/C:Cdc20 Mediated Degradation Of Cyclin B Pathway | APC/C:Cdc20 Mediated Degradation Of Cyclin B Pathway |
| APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins Pathway | APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins Pathway |
| APC:Cdc20 Mediated Degradation Of Cell Cycle Proteins Prior To Satisfation Of The Cell Cycle Checkpoint Pathway | APC:Cdc20 Mediated Degradation Of Cell Cycle Proteins Prior To Satisfation Of The Cell Cycle Checkpoint Pathway |
| ARMS-mediated Activation Pathway | ARMS-mediated Activation Pathway |
| Activated TLR4 Signalling Pathway | Activated TLR4 Signalling Pathway |
| Activation Of APC/C And APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins Pathway | Activation Of APC/C And APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins Pathway |
| Activation Of NIMA Kinases NEK9, NEK6, NEK7 Pathway | Activation Of NIMA Kinases NEK9, NEK6, NEK7 Pathway |
| Anchoring Of The Basal Body To The Plasma Membrane Pathway | Anchoring Of The Basal Body To The Plasma Membrane Pathway |
| Assembly Of The Primary Cilium Pathway | Assembly Of The Primary Cilium Pathway |
Diseases associated with CDK1 ELISA Kit
| Carcinoma | publications with CDK1 and Carcinoma |
| Leukemia | publications with CDK1 and Leukemia |
| Adenocarcinoma | publications with CDK1 and Adenocarcinoma |
| Breast Neoplasms | publications with CDK1 and Breast Neoplasms |
| Lung Neoplasms | publications with CDK1 and Lung Neoplasms |
| Liver Diseases | publications with CDK1 and Liver Diseases |
| Liver Neoplasms | publications with CDK1 and Liver Neoplasms |
| Carcinoma, Hepatocellular | publications with CDK1 and Carcinoma, Hepatocellular |
| Neoplasms, Experimental | publications with CDK1 and Neoplasms, Experimental |
| Prostatic Neoplasms | publications with CDK1 and Prostatic Neoplasms |
Organs/Tissues associated with CDK1 ELISA Kit
| Liver | publications with CDK1 and Liver |
| Lung | publications with CDK1 and Lung |
| Blood | publications with CDK1 and Blood |
| Prostate | publications with CDK1 and Prostate |
| Brain | publications with CDK1 and Brain |
| Bone | publications with CDK1 and Bone |
| Vascular | publications with CDK1 and Vascular |
| Muscle | publications with CDK1 and Muscle |
| Kidney | publications with CDK1 and Kidney |
| Skin | publications with CDK1 and Skin |